
FHL2 Antibody


Rabbit Polyclonal Antigen Affinity Purified Catalog No. A300-333A Lot No. A300-333A-4		Protein ID GeneID	NP_963849.1 2274		BETHYL LABORATORIES, INC	
APPLICATIONS		WB, IP, IHC				
SPECIES REACTIVITY		Human, Mouse				
PRESUMED REACTIVITY		Based on 100% sequence identity, this antibody is predicted to react with Rat and Bovine				
AMOUNT		100 µl				
CONCENTRATION		1000 μg/ml				
STORAGE/SHELF LIFE		2 - 8° C / 1 year from date of receipt				
PHYSICAL STATE		Liquid				
BUFFER		Tris-citrate/phosphate buffer, pH 7 to 8 containing 0.09% Sodium Azide				
ISOTYPE		IgG				
ORIGIN		USA				
PRODUCTION PROCEDURES		Antibody was affinity purified using an epitope specific to FHL2 immobilized on solid support.				
PROCEDURES		The epitope recognized by A300-333A maps to a region between residue 225 and the C- terminus (residue 279) of human Four and a Half LIM domains 2 using the numbering given in entry NP_963849.1 (GeneID 2274). Immunoglobulin concentration was determined by extinction coefficient: absorbance at 280 nm				
		of 1.4 equals 1.0 mg of IgG.				
APPLICATIONS		Centrifuge tube to remove product from lid. Optimal working dilutions should be determined experimentally by the investigator. Prepare working dilution immediately before use.				
		Western Blot	1:2	,000 - 1:10,000		
		Immunoprecip	itation 2 -	5 µg/mg lysate		
		Immunohistoc		,000 to 1:5,000. Epitope ommended for FFPE tissu		EDTA pH9.0 is
APPLICATION NOTES		Western blot of immunoprecipitates performed using Normal Pig Serum (Cat. No. S100–020), Goat anti–Rabbit Light Chain HRP Conjugate (Cat. No. A120–113P) and 4–20% SDS–PAGE (link to IP–western blot protocol in Additional Info section below).				
IHC HUMAN CONTROLS		Western blot of lysates performed using standard western blot reagents and 4–20% SDS-PAGE. Breast Carcinoma, Ovarian Carcinoma, Prostate Carcinoma				
ADDITIONAL INFO		https://www.bethyl.com/product/A300-333A Use the link above to view SDS, a current list of citations, and other product specific information. IP-western blot protocol: https://www.bethyl.com/content/protocol_IP_WB				

This document certifies that this product has met all of the quality control standards defined by Bethyl Laboratories, Inc. Eric McIntush, PhD | Chief Scientific Officer Date: June 21, 2019

For in vitro laboratory use only. Not for any clinical, therapeutic or diagnostic use in humans or animals. Not for human or animal consumption. This product may not be resold or modified for resale without the prior written approval of Bethyl Laboratories, Inc. The information provided in this data sheet is believed to be correct but does not purport to be all-inclusive and is intended to be used as a guide. Bethyl Laboratories, Inc. shall not be liable or responsible in any way for use of either this information or the material supplied. Disposal of hazardous material may be subject to federal, state or local laws or regulations.




HeLa |TCMK| 3T3 |Detection of human and mouse FHL2 by western blot.Samples: Whole cell lysate (50 µg) from HeLa, TCMK-1, andNIH 3T3 cells prepared using NETN lysis buffer. Antibody:Affinity purified rabbit anti-FHL2 antibody A300-333A (lotA300-333A-4) used for WB at 0.1 µg/ml. Detection:Chemiluminescence with an exposure time of 30 seconds.



Detection of human FHL2 by western blot of

immunoprecipitates. *Samples:* Whole cell lysate (1.0 mg per IP reaction; 20% of IP loaded) from HeLa cells prepared using NETN lysis buffer. *Antibodies:* Affinity purified rabbit anti-FHL2 antibody A300-333A (lot A300-333A-4) used for IP at 3 µg per reaction. FHL2 was also immunoprecipitated by rabbit anti-FHL2 antibody A300-332A. For blotting immunoprecipitated FHL2, A300-333A was used at 1 µg/ml. *Detection:* Chemiluminescence with an exposure time of 30 seconds.



Detection of human FHL2 by immunohistochemistry. *Sample:* FFPE section of human ovarian carcinoma. *Antibody:* Affinity purified rabbit anti-FHL2 (Cat. No. A300-333A Lot 4) used at a dilution of 1:2000 (0.5µg/ml). *Detection:* DAB